A share price of Inhibikase Therapeutics Inc [IKT] is currently trading at $1.89, up 2.16%. An important factor to consider is whether the stock is rising or falling in short-term value. The IKT shares have gain 14.55% over the last week, with a monthly amount drifted -6.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inhibikase Therapeutics Inc [NASDAQ: IKT] stock has seen the most recent analyst activity on February 12, 2025, when H.C. Wainwright downgraded its rating to a Neutral.
Inhibikase Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.12 and $4.20. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Inhibikase Therapeutics Inc [NASDAQ: IKT] shares were valued at $1.89 at the most recent close of the market. An investor can expect a potential return of 243.92% based on the average IKT price forecast.
Analyzing the IKT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.79 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8267 points at the first support level, and at 1.7633 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9267, and for the 2nd resistance point, it is at 1.9633.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inhibikase Therapeutics Inc [NASDAQ:IKT] is 11.01. On the other hand, the Quick Ratio is 11.01, and the Cash Ratio is 8.59.
Transactions by insiders
Recent insider trading involved Bellini Roberto, Director, that happened on Oct 21 ’24 when 1.46 million shares were purchased. Director, Kush Arvind completed a deal on Oct 21 ’24 to buy 0.14 million shares. Meanwhile, Director Munshi Amit bought 0.36 million shares on Oct 21 ’24.
